Bill Fegley, president of Puravair, the distributor responsible for the introduction of the ViraTech UV-400 to the Boston medical market, said: “These are two of the finest medical institutions in the world today. Hospitals generally look for ways to stay ahead of the curve regarding the safety of their patients and staff. These two particular hospitals are well known for their proactive approach in this area. Given the UV-400's FDA clearance rating and lab test results which prove the unit kills over 99% of bacteria with every pass, how could any hospital not want to evaluate these units? We are thrilled with the feedback we're getting from both hospitals, both of which have stated that the hospital staff are noticing less coughing and respiratory symptoms within the first week of operation of the ViraTech units.”